Bacterial Vaginosis: An In-Depth Analysis of Pathophysiology, Clinical Presentation, and Emerging Therapeutic Challenges

Suhaira Rashid Ghauri[1], Huda Shami[2], Humera Nazir[3], Bibi Saima[4], Sana Javed[5], Samreen Hashmi[6], Saleha Tahir[7,*] and Arooj Arshad[8]

[1]Department of Microbiology, The University of Faisalabad, Pakistan
[2]Department of Dermal Sciences, The University of Faisalabad, Pakistan
[3]Department of Microbiology and Molecular Genetics, Bahauddin Zakariya University Multan, Pakistan
[4]Department of Microbiology, University of Agriculture Faisalabad, Pakistan
[5]Department of Pharmacy, The University of Faisalabad, Lahore
[6]Department of wildlife and Ecology, University of Veterinary and Animal Sciences Lahore, Pakistan
[7]Department of Parasitology, University of Agriculture Faisalabad, Pakistan
[8]Department of Biochemistry and Biotechnology, The University of Faisalabad, Pakistan
*Corresponding author: salehatahir999@gmail.com

Abstract

The vaginal microbiota, predominantly determined by Lactobacillus species, has a significant impact on women's health through the production of lactic acid, which maintains a low pH in the vagina and prevents the development of detrimental pathogens. A vaginal infection known as bacterial vaginosis; results from a disturbance in microbial ecosystem equilibrium, favoring the growth of anaerobic bacteria such as *Atopobium vaginae* and *Gardnerella vaginalis*, along with a loss of Lactobacillus species. Dysbiosis, the imbalance of vaginal microbiota, is marked by increased susceptibility to Sexually Transmitted Infections (STIs), Pelvic Inflammatory Disease (PID), Adverse Pregnancy Outcomes (APOs), and persistent infections. Although diagnosing bacterial vaginosis uses clinical strategies, such as variability among observers, these methods may have limitations. Advances in molecular diagnostics, like Next-generation sequencing, have enhanced our understanding of bacterial vaginosis mechanisms, emphasizing the activity of biofilms and the interactions among different microbial species that play a crucial role in disease relapse and persistence. Despite all therapeutic strategies or treatments, bacterial vaginosis recurs in 50% of women after almost six months. The global burden of BV can be alleviated through advancements in research and innovation, ultimately benefiting women's health and well-being.

Keywords: Vaginal microbiota, Bacterial vaginosis, Sexually Transmitted Infections, Therapeutic strategies

Cite this Article as: Ghauri SR, Shami H, Nazir H, Saima B, Javed S, Hashmi S, Tahir S, and Arshad A, 2025. Bacterial vaginosis: an in-depth analysis of pathophysiology, clinical presentation, and emerging therapeutic challenges. In: Ismael SS, Nisa QU, Nisa ZU and Aziz S (eds), Diseases Across Life: From Humans to Land and Sea. Unique Scientific Publishers, Faisalabad, Pakistan, pp: 125-131. https://doi.org/10.47278/book.HH/2025.232

A Publication of Unique Scientific Publishers

Chapter No: 25-018

Received: 19-Feb-2025
Revised: 15-March-2025
Accepted: 06-Apr-2025

Introduction

Vaginal microbiome is the well-defined region of the human microbiota. The vaginal microbiota is established by the bacteria that are fundamental in maintaining homeostasis and women's health. Lactobacilli species are the most dominant among all bacteria. The loss of balance in the vaginal microbiota encourages various infections such as bacterial vaginosis (Diop et al., 2019). The excess of pathogens, including *Gardnerella* spp., *Prevotella* spp., *Mobilincus* species, *Megaspahera* spp., *Sneathea* spp., and mixed vaginal anaerobes, can cause BV. This microbiota is characterized by low levels of diversity and a dynamic composition that changes in response to various endogenous and exogenous factors (Yoo et al., 2022).

Ironically, an increase in microbial diversity may indicate Dysbiosis, such as bacterial vaginosis (BV). Women's health is greatly influenced by the vaginal microbiota, which also effect the fatal development, infections, and reproductive outcomes. Bacterial Vaginosis or Vaginal Dysbiosis, is one of the most common vaginal conditions and is linked to abnormal changes in vaginal microbiota. BV poses a serious public health risk to women of reproductive age, their offspring, and their partners since it is associated with poor reproductive health outcomes. Preterm birth, miscarriage, pelvic inflammatory disease, and an elevated risk of HIV acquisition and transmission are among them. More than 100 trillion microbial communities that live in the human gut. It has a mutualistic relationship with its host and plays a significant role in the host's metabolism by, for example, producing vitamins and other metabolites that are essential to the host's physiology. (Okoth et al., 2020). Therefore, severe alterations in the makeup and activity of intestinal microbe, known as gut microbiota Dysbiosis, are linked to neurological, respiratory, metabolic, hepatic, and cardiovascular diseases in addition to gastroenteritis. Although they are present in extra intestinal organs such the epidermis, nasal and oral cavities, and vagina, bacteria do not outnumber 1012/g in

these areas. A Dysbiosis of the vaginal microbiota is characterized by a shift from Lactobacilli dominance to a combination of other anaerobic bacteria, BV is very common vaginal infections among women of reproductive age worldwide. Traditional antibiotic therapy often fails, and the pathophysiology of BV is still poorly understood, with an estimated 50% relapse rate at six-month follow-up (Abou Chacra et al., 2022). A laboratory test making use of the Nugent scoring system or a clinical assessment using Amsel's criteria can be used to diagnose BV. Both strategies have shortcomings, especially the heterogeneity between observers, which can compromise the precision of the diagnosis depending on the education and experiences of the assessor, even though they are widely used and considered the "gold standard" for BV diagnosis. Two significant barriers to the development of innovative diagnostic assays are the absence of a common case definition and our incomplete understanding of the genesis of BV (Sobel & Sobel, 2021). Next-generation sequencing (NGS) and further recent advancements in molecular and high-throughput sequencing technologies have proven that BV is complex, impacted by host, microbiological, epidemiological, and social factors. Characteristic diagnostic methods, identification of Bacterial vaginosis, and treatment strategies are the main focus of this study.

Pathophysiological Mechanisms

Bacterial vaginosis (BV) is polymicrobial disorder of the lower genital tract that is indicated by the dysbiosis- change in the composition of the vaginal microbiota that leads to the deprivation of lactobacillus, raise in the vaginal pH and enhanced growth of detrimental gram-negative and positive facultative or obligate anaerobic bacteria, such as *Gardnerella vaginalis*, *Atopobium vaginae*, *Ureaplasma urealyticum*, *Mycoplasma hominis*, *Leptotrichia* spp., and some others. The particular constitution of vagina can vary in different women. The anaerobic coccobacillus, *Gardnerella vaginalis*, is a persistent suspect in the pathophysiology and diagnosis of bacterial vaginosis (Amabebe & Anumba, 2022). Additionally, one important factor in the etiology of bacterial vaginosis is the development of polymicrobial biofilm, in which bacteria associated with BV form biofilm and become more resistant to specific antibiotic treatment strategies, and easily protect themselves from the host's immune system. The composition of a biofilm is influenced by the harmful bacterial strains present in the vaginal microbiota, vaginal pH and surface characteristics that lead to pain, irregular discharge and inflammation of the vaginal mucosa shown in Fig. 1 (Carson et al., 2021).



Fig. 1: Highlights the pathophysiological processes that lead to the disturbance of vaginal homeostasis, emphasizing the roles played by inflammation, biofilm formation, pH imbalance, and Lactobacillus depletion (Rederived from Biorender).

This is a thorough explanation:

1. Normal State (pH < 4.5): Lactobacillus species produce "lactic acid" and hydrogen ions (H+) to maintain the vaginal pH below 4.5 under normal conditions (Navarro et al., 2023). These acidic condition aids in maintaining the mucous layer and epithelial barrier while inhibiting the development of pathogenic microbes.
2. Lactobacillus Depletion: Less lactic acid is produced when Lactobacillus populations are disturbed (for instance, by drugs, hormonal changes, or infections). As a result, the pH of the vagina increase (to >4.5), which makes the environment more conducive to the development of harmful bacteria (Das & Konwar, 2024).
3. Pathogen Overgrowth: When Lactobacillus is absent, opportunistic pathogens (such as *Gardnerella vaginalis* or other anaerobes) proliferate. These infections use enzymatic activity to break down the protective mucus layer.
4. Inflammation and Cytolysis: Toxins and enzymes emitted by pathogens that lead to inflammation and epithelial cell cytolysis, or cell death (Lucas et al., 2020). This increases the risk of infection even more and contributes to breaking down the epithelial barrier.
5. Biofilm Formation: Harmful bacteria adapt to envelope themselves in a protective layer, biofilm that leads to the development of antibiotic resistance, which causes uncontrolled, long-lasting microbial infections (Rather et al., 2021).
6. Disruption of mucosal barrier: the disrupted vaginal barrier leads to the loss of membrane function which helps bacterial vaginosis to overcome the host defense and antimicrobial substances which causes more occurrence of infections (Amabebe & Anumba, 2022).

An overview of Pathophysiology

Trigger: An outstanding reduction in the Lactobacillus species provides an ideal environment for the pathogen's growth, which affects women in different ways, such as bacterial vaginosis or other reproductive health issues (Sadeghpour Heravi, 2024). Ultimately the vaginal barrier is disturbed, leading to the elevated risk of bacterial vaginosis, infertility, pelvic inflammatory disease, sexually transmitted infections, and other upper genital tract infections (Ravel et al., 2021).

Mechanisms of Biofilm Protection

H2O2 (Hydrogen Peroxide) and Antibiotic Resistance

By providing physical protection against hydrogen peroxide, which produced by the typical lactobacilli in the vagina, the biofilm structure helps to maintain a healthy vaginal environment. By protecting the bacteria in biofilms, the harmful effects of H2O2 are reduced, allowing the BV-associated germs to thrive (Pendharkar et al., 2023). It is recognized that biofilms can spread antibiotic resistance. This resistance arises because the biofilm matrix inhibits antibiotic penetration and because the bacteria within the biofilm may be in a metabolically inactive condition, making them less vulnerable to medications that target active activity (Khan et al., 2021). When bacteria in biofilms exchange genes linked to antibiotic resistance, treatment becomes even more challenging.

Clinical Implications

Many facets of women's health are significantly impacted clinically by bacterial vaginosis. Women with BV are more susceptible to STIs, including HIV, due to alteration in the vaginal environment that may impair the immune system and mucosal barrier. There may be a greater risk of contracting and spreading illnesses like gonorrhea and chlamydia when BV is present (Aljamali et al., 2021). Furthermore, it has been demonstrated that Bacterial vaginosis is associated with tubal infertility as well as enhanced risk of preclinical pregnancy loss, preterm delivery, and voluntary abortion, and also impacts pregnancy consequences. Additionally, following a hysterectomy, surgical abortion, or delivery, bacterial vaginosis increases the possibility of obstetric and gynecological postoperative site infections. Multiple adverse outcomes, including long duration stays at the hospital, reoperations, or sepsis, are correlated to these infections (Soper, 2020). Moreover, bacterial vaginosis poses a threat to women's reproductive wellness, emotional health, and financial well-being. Women's hygiene practices, socioeconomic status, medical history, and other factors are included in the risk aspects. These detrimental characteristics change the vaginal immunity and endocrine function which facilitates the recurrence of bacterial vaginosis (Zeng et al., 2023). Additionally, BV has been associated with a higher prevalence of other disorders that may impact cervical health, such as cervical infections. With relapse rates of roughly 50% within six months of treatment, many women continue to have more complex issues. The consequences of BV highlight the significance of the early identification of women at risk, effective treatment, and the provision of all-encompassing management techniques.

Normal Vaginal Microbiome

Normal vaginal Microbiome Lactobacilli create hydrogen peroxide and bacteriocins, two antibacterial compounds that help shield the vagina from infection (Miko & Barakonyi, 2023). This stability in microbiota is crucial to intercept Dysbiosis, a state characterized by the imbalance of microbial populations in sexual health.

Microbiome Diversity: A Pathway to Optimal Vaginal Health

The vaginal microbiome, which is comprised mainly of different types of bacteria, is vitally important to women's reproductive health and overall health state (Kalia et al., 2020). The most widespread species in healthy people is Lactobacilli. The variety of microbial species present in vaginal environment is known as microbiome diversity, establishing a healthy balance is essential for both preventing infections and ensuring good health. A diversified and stabilized microbiome encourages the immune system by promoting a healthy inflammatory response, which reduces the risk of chronic inflammation associated with several reproductive health issues (Amabebe & Anumba, 2020). A balanced microbiota also improves the vagina's resistance to colonization by detrimental pathogens because different microbial communities produce metabolites and antimicrobial substances that interfere with growth of pathogen. Probiotics may assist in the remodeling and maintenance of a healthy vaginal microbiome, especially post antibiotic therapy. It is advised to conduct Gynecological examination to ensure good vaginal health and safety of the women. Women should also be informed about appropriate sexual habits or hygiene measures (Graziottin, 2024).

Diagnosis of BV

Appropriate diagnostic techniques are essential for diagnosing bacterial vaginosis infection. Traditionally, BV can be identified through microscopic and clinical processes, but these methods require time, expertise, and high specificity. Advanced diagnostic methods, such as highly specific and sensitive point-of-care (POC) tests, and the identification of biomarkers, can be employed to design the course of therapy and vaccines (Redelinghuys et al., 2020). It is also important to gain insights into the patient's history and follow the appropriate treatment method. Certain characteristics of vaginal discharge must be considered, such as onset, duration, menstruation time, odor, consistency, and colour (Vanishree & Tahir, 2020).

Amsel's Criteria

It is the most widely used method to clinically diagnose bacterial vaginosis. It was first introduced in 1983. It presents some of the aspects (a) a thin, uniform vaginal discharge with grayish-white colour, (b) a vaginal pH of >4.5, (c) a fishy odor indicating positive whiff test following the mixture of KOH and vaginal secretions), (d) at least 20% presence of clue cells per high-power field on wet mount of vaginal secretions. Clue cells are vaginal epithelial cells, showing a grainy border freckled appearance (Muzny et al., 2023).

Vaginal pH: The normal healthy vaginal microbiome is directed by Lactobacillus species that metabolize glycogen which leads to the lowering of vaginal pH (3.5-4.5). In the case of bacterial vaginosis, when lactobacilli are eradicated, and enhanced growth of other bacterial species occurs, the vaginal pH is raised to 4.5 or above.

Whiff test: The amine test, also called the Whiff test, is used to determine the presence of bacterial vaginosis if there is an ammoniacal smell. When the vaginal secretions are placed on a sterile glass slide, two drops of 10% KOH are added. The slide is mounted by setting down a cover slip on it. The slip should be devoid of trapped air bubbles. At the end, the slide is examined by a functioning microscope (Jishna et al., 2024).

System of Nugent Scoring

It is a popular method to identify bacterial vaginosis through the Gram-stained vaginal smears. This system was established by Dr. Robert Nugent in the 1980s for evaluating vaginal microbiota (Carson et al., 2021). The Nugent scoring is classified into three categories: (a) 0-3 as normal vaginal flora indicating Lactobacillus as "Dominant species", (b) 4-6 represents altered vaginal flora, (c) 7-10 indicates the presence of BV. However, a calculation by this score system consumes more time and could be affected by the technician's skill (Wang et al., 2021).

BV Symptoms and Their Effects on Health

According to some studies, almost 50-75% of women suffering from bacterial vaginosis don't show any symptoms. Others may experience vaginal discharge or odor. The discharge may appear thin, smooth, off-white, or grayish. Bacterial vaginosis has a typical undesirable "fishy odor". This vaginal odor becomes more dominant following sexual activities and during menstruation (Ellington et al., 2020). BV may not develop recognizable vaginal pain, redness or swelling that's why it becomes more challenging to diagnose bacterial vaginosis as compared to other infections. BV might have serious health hazards and repercussions if treatment is not obtained. One of the primary concerns is an increased susceptibility to STIs, such as chlamydia, gonorrhea, and HIV, as BV changes the natural vaginal flora and weakens the body's defenses against these illnesses (Vieira-Baptista & Bornstein, 2019). BV is linked to several obstetric problems in pregnant women, including low birth weight, late miscarriage, and premature delivery, because of infections that enter the reproductive system. As the changed vaginal microbiota can induce pathogenic bacteria to surgical areas, especially after surgeries such as hysterectomy or abortion, bacterial vaginosis can also increase the risk of post-surgical infection. Early development lessens these risks and improves reproductive health and the quality of life.

Treatment

An imbalance in the vaginal natural flora causes bacterial vaginosis, a frequent vaginal disease. Antimicrobial treatment is essential to restore balance and decrease symptoms like discomfort, odor, and irregular discharge (Corea et al., 2024). The most widely prescribed therapies for BV are described in Table 1, along with their duration, potential side effects, and administration methods. These treatments are subjected to eliminate detrimental bacteria, re-establish the vaginal microbiome, and prevent reappearance of disease (Mendonça et al., 2019). Although the main therapeutics are antibiotics like metronidazole and clindamycin, probiotics and boric acid can also be applicable as additional measures, especially in cases of recurrent bacterial vaginosis. Patients must go through the entire prescribed treatment to ensure the effective removal of the infection and reduce the possibility of consequences.

Table 1: Antimicrobial treatment of Bacterial vaginosis

Treatment Option	Description	Mode of Administration	Duration of Treatment	Common Side Effects	References
Antibiotics (Metronidazole)	The most often prescribed medicine for BV. It functions by preventing the growth of bacteria.	Oral (500 mg twice daily) or topical gel (5 g, once daily)	7 days (oral) or 5 days (topical)	Nausea, headache, metallic taste, vaginal irritation	(Anstey Watkins et al.,2019)
Clindamycin	An additional antibiotic alternative for BV treatment that works well against the overabundance of some bacteria.	Oral (300 mg twice daily) or vaginal cream (5 g, once at bedtime)	7 days	Diarrhea, nausea, vaginal discomfort, and risk of yeast infection	(Luchian et al., 2021)
Tinidazole	Like metronidazole, it is used to treat bacterial infections, including BV.	Oral (2 g once daily)	5 days	Nausea, headache, metallic taste, dizziness	(Abd El Aziz et al., 2019)
Probiotics	Probiotics may aid in reestablishing the proper balance of beneficial bacteria in vagina, even though they are not an antibiotic.	Oral supplements (various formulations)	Ongoing use, as recommended	Generally safe, mild digestive upset in some cases	(Mashatan et al., 2023)
Boric Acid	Boric Acid, a suppository treatment for recurrent BV, is believed to aid in restoring the microbial balance and vaginal Ph.	Vaginal suppositories (600 mg, once or twice daily)	7-14 days	Vaginal irritation, burning sensation	(Faught & Reyes, 2019).
Multidose Vaginal Gels	For moderate BV symptoms, Over-the-counter vaginal gels can be helpful. By hydrating and restoring vaginal Ph, they offer comfort.	Vaginal gel (varies by brand)	Typically used until symptoms resolve	Vaginal discomfort, burning, or irritation	(Potter & Panay, 2021)

Challenges in BV Treatment

Even though some antibiotics work well against the bacteria that cause bacterial vaginosis and provide some relief from the symptoms, the recurrence is typically possible in many patients with bacterial vaginosis after treatment. The incapability of antibiotics to completely eradicate the biofilm-associated bacteria of bacterial vaginosis may be the leading cause of the high relapse rate (between 50% and 67%) (Chen et al., 2021). The factors causing bacterial vaginosis are still ambiguous, but new advanced developments, such as Next-generation sequencing, show that bacterial vaginosis is complex and impacted by:

- Social factors.
- Epidemiological factors.
- Microbiological factors.
- Host factors.

1. Social Factors of BV Treatment and Management

The economic, behavioral, and cultural factors critically impact the treatment and management of bacterial vaginosis. Some of the social aspects are elaborated as: Awareness about Sexual Health: women lack the right information about the prevention and treatment of bacterial vaginosis due to the lack of resources, proper diagnosis of the disease or infection (Heidt et al., 2020).

Cultural Norms: Traditional attitudes towards hygiene practices increase the risk of bacterial vaginosis, so proper knowledge about preventive measures, treatment, and culturally competent medical care should be given to women (Davidson et al., 2022).

2. Epidemiological Factors in the BV Treatment and Management

High Prevalence and Recurrence: BV is a frequent vaginal infection especially among women following sexual activity. Almost 30-50% of cases relapse within six months of treatment (Cohen et al., 2020).

Sexual Behavior: BV is more likely to appear in cases involving multiple partners or unprotected sexual relations, regardless of being classified as an STI, making prevention more difficult (Workowski, 2021).

Co-infections: TB often occurs in association with HIV and chlamydia, which enhances susceptibility to STI transmission and makes the diagnosis more complicated.

3. Microbiological Factors in the BV Treatment and Management

Understanding microbiological components is pivotal for a personalized approach, decreasing the risk of recurrence, and addressing problems associated with antibiotic resistance (Bassetti et al., 2022). Microbiological factors include the bacterial environment of the vagina and the challenges of stabilizing it:

- Disturbance of the vaginal
- The Formation of Flora Biofilms
- Resistance to antibiotics
- Problems with the efficacy of Treatment)

4. Host Factors in the BV Treatment and Management

The distinct physical aspects of a woman that can impact the onset, progression, and treatment of BV include various host variables: Immunological System: Differences in immune responses influence susceptibility, severity, and effectiveness of treatment (Jacobsen and Klein, 2021). Hormonal Changes: The pregnancy and menopause impact pH and immunity of the vagina which elevates the risk of bacterial vaginosis.

Vaginal pH and Lactobacillus: Decreased Lactobacillus levels enhance pH, which contributes to the pathogenic bacteria and makes the treatment complex (Zoghi, 2021).

Genetics: Inherited predisposition may influence susceptibility and recurrent infections. Obesity, diabetes, and HIV, alters the microbiome of vagina which ultimately raises the risk of bacterial vaginosis.

Age & Sexual Activity: Bacterial vaginosis is more prevalent in sexually active women, although it can also influence women going through menopause (Van Gerwen, 2023).

Conclusion

A persistent vaginal dysbiosis, has leading health influences on women, including high susceptibility to sexually transmitted infections, adverse reproductive consequences, and repeated occurrence. Its complicating pathophysiology involves the development of Biofilm, reduction in lactobacillus species, and raised vaginal pH that provide resistance to antimicrobial therapy. Variability plagues clinical diagnosis, which has historically depended on Amsel's criteria or Nugent scoring. This emphasizes the need for next-generation sequencing (NGS) and other more accurate molecular diagnostic techniques. High recurrence rates highlight the limitations of antibiotics, which continue to be the cornerstone of BV treatment. Addressing this requires research into novel therapies such as targeted microbiota manipulation. Understanding the interactions between host, microbial, and environmental factors is crucial for better BV management. Globally, women's health and results can be significantly enhanced by comprehensive strategies that include state-of-the-art therapies, improved diagnostics, and preventative measures.

References

Diop, K., Dufour, J. C., Levasseur, A., & Fenollar, F. (2019). Exhaustive repertoire of human vaginal microbiota. *Human Microbiome Journal, 11*, 100051.

Abd El Aziz, M. A., Sharifipour, F., Abedi, P., Jahanfar, S., & Judge, H. M. (2019). Secnidazole for treatment of bacterial vaginosis: a systematic review. *BMC Women's Health, 19*, 1-12.

Abou Chacra, L., Fenollar, F., & Diop, K. (2022). Bacterial vaginosis: what do we currently know? *Frontiers in Cellular and Infection Microbiology, 11*, 672429.

Aljamali, N. M., Al-zubaidy, Z. H., & Enad, A. H. (2021). Bacterial infection and common bacterial diseases: A Review. *Pharmaceutical Nanotechnology, 3*, 13-23.

Amabebe, E., & Anumba, D. O. (2020). Female gut and genital tract microbiota-induced crosstalk and differential effects of short-chain fatty acids on immune sequelae. *Frontiers in Immunology, 11*, 2184.

Amabebe, E., & Anumba, D. O. (2022). Mechanistic insights into immune suppression and evasion in bacterial vaginosis. *Current Microbiology, 79*(3), 84.

Anstey Watkins, J., Ross, J. D., Thandi, S., Brittain, C., Kai, J., & Griffiths, F. (2019). Acceptability of and treatment preferences for recurrent bacterial vaginosis—Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial. *PloS One, 14*(11), e0224964.

Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023). Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. *Nature Reviews Drug Discovery*, *22*(5), 387-409.

Bassetti, S., Tschudin-Sutter, S., Egli, A., & Osthoff, M. (2022). Optimizing antibiotic therapies to reduce the risk of bacterial resistance. *European Journal of Internal Medicine, 99*, 7-12.

Carson, L., Merkatz, R., Martinelli, E., Boyd, P., Variano, B., Sallent, T., & Malcolm, R. K. (2021). The vaginal microbiota, bacterial biofilms and polymeric drug-releasing vaginal rings. *Pharmaceutics*, 13(5), 751.

Chen, X., Lu, Y., Chen, T., & Li, R. (2021). The Female Vaginal Microbiome in Health and Bacterial Vaginosis. *Frontiers in Cellular and Infection Microbiology*, *11*, 631972.

Cohen, C. R., Wierzbicki, M. R., French, A. L., Morris, S., Newmann, S., Reno, H., & Hemmerling, A. (2020). Randomized trial of lactin-V to prevent recurrence of bacterial vaginosis. *New England Journal of Medicine, 382*(20), 1906-1915.

Corea, G., Klein, R. D., Hanmer, J., Holmes, H. B., Hoskins, B., Kishwar, M., & Steinbacher, R. (2024). *Man-made women: How new reproductive technologies affect women*. Taylor & Francis, 1965.

Das, S., & Konwar, B. K. (2024). Influence of connatural factors in shaping vaginal microflora and ensuring its health. *Archives of Gynecology and Obstetrics, 309*(3), 871-886.

Davidson, N., Hammarberg, K., Romero, L., Fisher, J. (2022). Access to preventive sexual and reproductive health care for women from refugee-like backgrounds: a systematic review. *BMC Public Health, 22,* 403.

Ellington, Kelly DNP, APRN, WHNP-BC, RNC-OB; Saccomano, Scott J. PhD, RN, GNP-BC. (2020). *Recurrent bacterial vaginosis*. *The Nurse Practitioner, 45*(10): p 27-32.

Faught, B. M., & Reyes, S. (2019). Characterization and treatment of recurrent bacterial vaginosis. *Journal of Women's Health, 28*(9), 1218-1226

Graziottin, A. (2024). Maintaining vulvar, vaginal and perineal health: Clinical considerations. *Women's Health, 20*, 17455057231223716.

Heidt, B., Siqueira, W. F., Eersels, K., Diliën, H., van Grinsven, B., Fujiwara, R. T., & Cleij, T. J. (2020). Point of care diagnostics in resource-limited settings: A review of the present and future of PoC in its most needed environment. *Biosensors, 10*(10), 133.

Hildebrand, J. P., Carlson, K., & Kansagor, A. T. (2024). *Vaginitis*. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470302/

Jacobsen, H., & Klein, S. L. (2021). Sex differences in immunity to viral infections. *Frontiers in Immunology, 12,* 720952.

Javed, A., Parvaiz, F., & Manzoor, S. (2019). Bacterial vaginosis: An insight into the prevalence, alternative treatment regimen, and its associated resistance patterns. *Microbial Pathogenesis, 127*, 21-30.

Jazani, N. H., Savoj, J., Lustgarten, M., Lau, W. L., & Vaziri, N. D. (2019). Impact of gut dysbiosis on neurohormonal pathways in chronic kidney disease. *Diseases, 7*(1), 21.

Jishna, P., Khader, A., Dipin, P., & Bindu, V. (2024). Point-of-care testing in a patient with vaginal discharge. *Journal of Skin and Sexually Transmitted Diseases*, *6*(1), 80-82.

Kalia, N., Singh, J., & Kaur, M. (2020). Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. *Annals of Clinical Microbiology and Antimicrobials, 19,* 1-19.

Khan, J., Tarar, S. M., Gul, I., Nawaz, U., & Arshad, M. (2021). Challenges of antibiotic resistance biofilms and potential combating strategies: a review. *3 Biotech, 11*, 1-15.

Lucas, R., Hadizamani, Y., Gonzales, J., Gorshkov, B., Bodmer, T., Berthiaume, Y., & Hamacher, J. (2020). Impact of bacterial toxins in the lungs. *Toxins, 12*(4), 223.

Luchian, I., Goriuc, A., Martu, M. A., & Covasa, M. (2021). Clindamycin as an alternative option in optimizing periodontal therapy. *Antibiotics, 10*(7), 814.

Mashatan, N., Heidari, R., Altafi, M., Amiri, A., Ommati, M. M., & Hashemzaei, M. (2023). Probiotics in vaginal health. *Pathogens and Disease, 81*, ftad012.

Mendonça, A. A., da Silva, P. K. N., Calazans, T. L. S., de Souza, R. B., de Barros Pita, W., Elsztein, C., & de Morais Junior, M. A. (2019). Lactobacillus vini: mechanistic response to stress by medium acidification. *Microbiology, 165*(1), 26-36.

Miko, E., & Barakonyi, A. (2023). The role of hydrogen-peroxide (H2O2) produced by vaginal microbiota in female reproductive health. *Antioxidants, 12*(5), 1055.

Mohankumar, B., Shandil, R. K., Narayanan, S., & Krishnan, U. M. (2022). Vaginosis: Advances in new therapeutic development and microbiome restoration. *Microbial Pathogenesis, 168,* 105606.

Muzny, C. A., Cerca, N., Elnaggar, J. H., Taylor, C. M., Sobel, J. D., & Van Der Pol, B. (2023). State of the art for diagnosis of bacterial vaginosis. *Journal of Clinical Microbiology, 61*(8), e00837-22.

Navarro, S., Abla, H., Colmer-Hamood, J. A., Ventolini, G., & Hamood, A. N. (2023). Under conditions closely mimicking vaginal fluid, Lactobacillus jensenii strain 62B produces a bacteriocin-like inhibitory substance that targets and eliminates *Gardnerella species*. *Microbiology, 169*(11), 001409.

Okoth, K., Chandan, J. S., Marshall, T., Thangaratinam, S., Thomas, G. N., Nirantharakumar, K., & Adderley, N. J. (2020). Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. *British Medical Journal*, *371*.

Pendharkar, S., Skafte-Holm, A., Simsek, G., & Haahr, T. (2023). Lactobacilli and their probiotic effects in the vagina of reproductive age women. *Microorganisms, 11*(3), 636.

Potter, N., & Panay, N. (2021). Vaginal lubricants and moisturizers: a review into use, efficacy, and safety. *Climacteric, 24*(1), 19-24.

Rather, M. A., Gupta, K., & Mandal, M. (2021). Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies. *Brazilian Journal of Microbiology*, 1-18.

Ravel, J., Moreno, I., Simón, C. (2021). Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease. *American Journal of Obstetrics and Gynecology, 224*(3), 251-257.

Redelinghuys, M. J., Geldenhuys, J., Jung, H., & Kock, M. M. (2020). Bacterial Vaginosis: Current Diagnostic Avenues and Future Opportunities. *Frontiers in Cellular and Infection Microbiology, 10*, 521070.

Sadeghpour Heravi, F. (2024). Host-vaginal microbiota interaction: shaping the vaginal microenvironment and bacterial vaginosis. *Current Clinical Microbiology Reports*, *11*(3), 177-191.

Salam, M. A., Al-Amin, M. Y., Pawar, J. S., Akhter, N., & Lucy, I. B. (2023). Conventional methods and future trends in antimicrobial susceptibility testing. *Saudi Journal of Biological Sciences, 30*(3), 103582.

Simon, J. C., Marchesi, J. R., Mougel, C., & Selosse, M. A. (2019). Host-microbiota interactions: from holobiont theory to analysis. *Microbiome, 7,* 1-5.

Sobel, J. D., & Sobel, R. (2021). Current and emerging pharmacotherapy for recurrent bacterial vaginosis. *Expert Opinion on Pharmacotherapy*, *22*(12), 1593-1600.

Soper, D., E. (2020). Bacterial vaginosis and surgical site infections. *American Journal of Obstetrics and Gynecology, 222*(3), 219-223.

Sushma, B. N. (2020). *Microbiological Profile in Women with Symptomatic Vaginal Discharge* (Master's thesis, Rajiv Gandhi University of Health Sciences (India)). 30579195.

Torcia, M. G. (2019). Interplay among vaginal microbiome, immune response and sexually transmitted viral infections. *International Journal of Molecular Sciences, 20*(2), 266.

Van Gerwen, O. T., Smith, S. E., & Muzny, C. A. (2023). Bacterial vaginosis in postmenopausal women. *Current Infectious Disease Reports, 25*(1), 7-15.

Vieira-Baptista, P., & Bornstein, J. (2019). Candidiasis, bacterial vaginosis, trichomoniasis and other vaginal conditions affecting the vulva. In *Vulvar Disease: Breaking the Myths* (pp. 167-205). Cham: Springer International Publishing.

Workowski, K. A. (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. *Recommendations and Reports*, 70.

Yoo, J. J., Song, J. S., Kim, W. B., Yun, J., Shin, H. B., Jang, M. A., ... & SMS (Soonchunhyang Microbiome Multi-Disciplinary Study Group). (2022). Gardnerella vaginalis in recurrent urinary tract infection is associated with dysbiosis of the bladder microbiome. *Journal of Clinical Medicine*, *11*(9), 2295.

Zeng, X., An, R. & Li, H. (2023). Risk factors of recurrent bacterial vaginosis among women of reproductive age: A cross-sectional study. *Open Medicine*, *18*(1), 20230743.

Zoghi, A., Massoud, R., Todorov, S. D., Chikindas, M. L., Popov, I., Smith, S., & Khosravi-Darani, K. (2021). Role of the lactobacilli in food bio-decontamination: Friends with benefits. *Enzyme and Microbial Technology, 150*, 109861.